US FDA advises of risk factor for PML, gives go ahead for test

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1386, 2012-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The US FDA advises against filling prescriptions outside of the US due to the risk of being given the wrong drug.

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 495, 2006-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

US FDA advises caution for recombinant erythropoietins

By  

Inpharma, Vol. 1, Iss. 1565, 2006-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

US FDA advises caution for recombinant erythropoietins

By  

Reactions Weekly, Vol. 1, Iss. 1129, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Rituxan associated with PML, warns US FDA

By  

Reactions Weekly, Vol. 1, Iss. 1133, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Rituxan associated with PML, warns US FDA

By  

Inpharma, Vol. 1, Iss. 1569, 2007-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite